These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31745297)

  • 1. Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer.
    Kumarasamy V; Ruiz A; Nambiar R; Witkiewicz AK; Knudsen ES
    Oncogene; 2020 Feb; 39(9):1831-1845. PubMed ID: 31745297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma.
    Salvador-Barbero B; Álvarez-Fernández M; Zapatero-Solana E; El Bakkali A; Menéndez MDC; López-Casas PP; Di Domenico T; Xie T; VanArsdale T; Shields DJ; Hidalgo M; Malumbres M
    Cancer Cell; 2020 Mar; 37(3):340-353.e6. PubMed ID: 32109375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
    Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
    Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
    Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
    Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
    Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
    Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.
    Witkiewicz AK; Borja NA; Franco J; Brody JR; Yeo CJ; Mansour J; Choti MA; McCue P; Knudsen ES
    Oncotarget; 2015 Jun; 6(18):15788-801. PubMed ID: 26158861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
    Heilmann AM; Perera RM; Ecker V; Nicolay BN; Bardeesy N; Benes CH; Dyson NJ
    Cancer Res; 2014 Jul; 74(14):3947-58. PubMed ID: 24986516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
    Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
    Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine.
    Miller AL; Fehling SC; Vance RB; Chen D; Brown EJ; Hossain MI; Heard EO; Andrabi SA; Wang H; Yang ES; Buchsbaum DJ; van Waardenburg RCAM; Bellis SL; Yoon KJ
    Cancer Lett; 2024 Jun; 592():216919. PubMed ID: 38704133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
    Huang X; Di Liberto M; Jayabalan D; Liang J; Ely S; Bretz J; Shaffer AL; Louie T; Chen I; Randolph S; Hahn WC; Staudt LM; Niesvizky R; Moore MA; Chen-Kiang S
    Blood; 2012 Aug; 120(5):1095-106. PubMed ID: 22718837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer.
    D'Costa Z; Jones K; Azad A; van Stiphout R; Lim SY; Gomes AL; Kinchesh P; Smart SC; Gillies McKenna W; Buffa FM; Sansom OJ; Muschel RJ; O'Neill E; Fokas E
    Cancer Res; 2017 Nov; 77(21):5952-5962. PubMed ID: 28765154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer.
    Knudsen ES; Kumarasamy V; Ruiz A; Sivinski J; Chung S; Grant A; Vail P; Chauhan SS; Jie T; Riall TS; Witkiewicz AK
    Oncogene; 2019 May; 38(18):3355-3370. PubMed ID: 30696953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
    Le Calvé B; Griveau A; Vindrieux D; Maréchal R; Wiel C; Svrcek M; Gout J; Azzi L; Payen L; Cros J; de la Fouchardière C; Dubus P; Guitton J; Bartholin L; Bachet JB; Bernard D
    Oncotarget; 2016 May; 7(22):32100-12. PubMed ID: 27050073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L; Yao J; Li W; Zhang C
    Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.
    Franco J; Witkiewicz AK; Knudsen ES
    Oncotarget; 2014 Aug; 5(15):6512-25. PubMed ID: 25156567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
    Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
    Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
    J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.